TABLE 1.

Randomised phase III trials comparing tyrosine kinase inhibitors with best supportive care as salvage therapy

First author [ref.]	Treatment arm	Patients n	Objective response %	p-value	Median survival months	p-value
Shepherd [2]	Erlotinib	488	8.9	<0.001	6.7	<0.001
	Placebo	243	1		4.7
Thatcher [3]	Gefitinib	1129	8	<0.0001	5.6	0.09
	Placebo	563	1.3		5.1